AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9631218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT) at the end of the birch pollen season in summer
Number of subjects: 58
Study 9631218 — intervention group
Group type: COMPARATOR
Intervention: Subgroup of 19 non-atopic symptom-free runners
Number of subjects: 58
Study 9631218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both winter and pollen season ECT
Number of subjects: 58
Study 8161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 286
Study 8161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 286
Study 8161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 286
Study 8161001 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 286
Study 3123619 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 179
Study 3123619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 30131565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (7 mg/24 h)
Number of subjects: 32
Study 30131565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27798210 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg intravenous solithromycin
Number of subjects: 48
Study 27798210 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral moxifloxacin
Number of subjects: 48
Study 27798210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26139388 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning with Web-based virtual patients (VPs) and standard PBLS training
Number of subjects: 57
Study 26139388 — intervention group
Group type: COMPARATOR
Intervention: Standard PBLS training (control group)
Number of subjects: 57
Study 24432626 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills + levofloxacin
Number of subjects: 80
Study 24432626 — intervention group
Group type: COMPARATOR
Intervention: levofloxacin
Number of subjects: 80
Study 21668635 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL + TAC (week 13 TAC elimination)
Number of subjects: 443
Study 21668635 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL + MMF
Number of subjects: 443
Study 21668635 — intervention group
Group type: COMPARATOR
Intervention: TAC + MMF
Number of subjects: 443
Study 18316457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment for mild-moderate dementia
Number of subjects: 0
Study 18316457 — intervention group
Group type: COMPARATOR
Intervention: Mini Mental State examination
Number of subjects: 0
Study 17047215 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training (IMT)
Number of subjects: 279
Study 17047215 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study 12726868 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (three-hour sessions targeting PPE use)
Number of subjects: 400
Study 12726868 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 400
Study 11584255 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 243
Study 11584255 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifying system (HHS)
Number of subjects: 243
Study 9604126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 600 mg after overnight fasting
Number of subjects: 12
Study 9604126 — intervention group
Group type: COMPARATOR
Intervention: Rufinamide 600 mg after a fat and protein rich breakfast
Number of subjects: 12
Study 7973238 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model for a repeated measures clinical trial with proliferative index data
Number of subjects: 0
Study 7973238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot randomized clinical trial
Number of subjects: 0
Study 2513931 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle aspiration + Metronidazole 2.4 g/day for 10 days
Number of subjects: 39
Study 2513931 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 2.4 g/day for 10 days
Number of subjects: 39
Study 1092444 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic therapy initiated preoperatively, with moderately high dosage for short periods.
Number of subjects: 0
Study 1092444 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0
Study 1092444 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique
Number of subjects: 0
Study 30999260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy, starting dose 1600 mg QD (or 1200 mg if previously reduced), adjustable between 800–2400 mg QD.
Number of subjects: 274
Study 30999260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy
Number of subjects: 274
Study 28253839 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CKD Care
Number of subjects: 442
Study 28253839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatments)
Number of subjects: 442
Study 25227704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 25227704 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 23266241 — intervention group
Group type: EXPERIMENTAL
Intervention: High vibration (45Hz, 5mm)
Number of subjects: 11
Study 23266241 — intervention group
Group type: COMPARATOR
Intervention: Low vibration (30Hz, 5mm)
Number of subjects: 11
Study 23266241 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 11
Study 21897336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl alcohol-intoxicated patients (mean ethyl alcohol, 251 [SD, 87] mg/dL)
Number of subjects: 121
Study 21897336 — intervention group
Group type: COMPARATOR
Intervention: Control group (sober and healthy)
Number of subjects: 121
Study 21897336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol infusions combined with initial oral alcohol load up to a blood alcohol steady state of 100 mg/dL (healthy volunteers, n = 12)
Number of subjects: 121
Study 18452779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 30 mg/day plus conventional calcium-channel blocker (CCB) therapy
Number of subjects: 64
Study 18452779 — intervention group
Group type: COMPARATOR
Intervention: Conventional calcium-channel blocker (CCB) therapy
Number of subjects: 64
Study 16492692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d) for 36 months
Number of subjects: 22
Study 16492692 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 22
Study 12953799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake with adequate calcium and magnesium
Number of subjects: 6
Study 12953799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 6
Study 10848662 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (2 mg b.d. administered orally)
Number of subjects: 25
Study 10848662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9095005 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification system based on historical and ECG factors
Number of subjects: 626
Study 9095005 — intervention group
Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 626
Study 8466367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 4 g/day for 21 days plus aminoglycoside for 10 days
Number of subjects: 20
Study 8466367 — intervention group
Group type: COMPARATOR
Intervention: Traditional medical management (beta lactam plus aminoglycoside for 21 to 50 days)
Number of subjects: 20
Study 31429944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain condition (painful stimuli)
Number of subjects: 30
Study 31429944 — intervention group
Group type: COMPARATOR
Intervention: No pain condition (nonpainful stimuli)
Number of subjects: 30
Study 30829308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunica vaginalis (TV) flap
Number of subjects: 0
Study 30829308 — intervention group
Group type: COMPARATOR
Intervention: Preputial dartos (PD) fascia
Number of subjects: 0
Study 29905456 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye makeup remover with Ocusoft®
Number of subjects: 0
Study 29905456 — intervention group
Group type: COMPARATOR
Intervention: Eye makeup remover with water
Number of subjects: 0
Study 25240454 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal MPS
Number of subjects: 400
Study 25240454 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 400
Study 25240454 — intervention group
Group type: COMPARATOR
Intervention: Invasive-medical strategy
Number of subjects: 400
Study 22704412 — intervention group
Group type: EXPERIMENTAL
Intervention: salvianolate combined with alprostadil and reduced glutathione liquid intravenously for 7 to 10 days, repeated monthly for four years
Number of subjects: 30
Study 22704412 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with the same oral medicines
Number of subjects: 30
Study 20713181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Method 1 - Mail only
Number of subjects: 623
Study 20713181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Method 2 - Mail and selective phone calls
Number of subjects: 623
Study 20713181 — intervention group
Group type: EXPERIMENTAL
Intervention: New Mexico Method 3 - Mail and non-selective phone calls
Number of subjects: 623
Study 18950181 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw broccoli
Number of subjects: 8
Study 18950181 — intervention group
Group type: COMPARATOR
Intervention: Cooked broccoli
Number of subjects: 8
Study 16000178 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic voting system
Number of subjects: 102
Study 11897269 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO[4:1] meal
Number of subjects: 15
Study 11897269 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL[1:1] meal
Number of subjects: 15
Study 11897269 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO[1:4] meal
Number of subjects: 15
Study 11897269 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL[1:1] and PRO[1:4] meals
Number of subjects: 15
Study 9890391 — intervention group
Group type: EXPERIMENTAL
Intervention: E5510 (20 mg)
Number of subjects: 9
Study 9890391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 9
Study 9890391 — intervention group
Group type: EXPERIMENTAL
Intervention: E5510
Number of subjects: 9
Study 9890391 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9
Study 8808232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg daily for 4 months
Number of subjects: 25
Study 8808232 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 25
Study 1773690 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin
Number of subjects: 50
Study 1773690 — intervention group
Group type: COMPARATOR
Intervention: Dry sterile occlusive dressing (Control)
Number of subjects: 50
Study 7171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about the surgical procedure and its effects
Number of subjects: 60
Study 7171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive coping technique
Number of subjects: 60
Study 7171880 — intervention group
Group type: EXPERIMENTAL
Intervention: General information about the ward
Number of subjects: 60
Study 7171880 — intervention group
Group type: COMPARATOR
Intervention: Declined psychological help
Number of subjects: 60
Study 30284597 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 with diltiazem (240 mg/day)
Number of subjects: 34
Study 30284597 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468
Number of subjects: 34
Study 30284597 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 after a high-fat high-calorie breakfast
Number of subjects: 34
Study 30284597 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ACT‐541468 alone or in combination with diltiazem, midazolam, or food
Number of subjects: 34
Study 29054803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 35
Study 29054803 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotaping (KT)
Number of subjects: 35
Study 26296296 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL exposure of 0, 7, 8, or 10 J/cm2
Number of subjects: 16
Study 26296296 — intervention group
Group type: COMPARATOR
Intervention: UVR exposure (three standard erythema doses)
Number of subjects: 16
Study 26296296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IPL and UVR
Number of subjects: 16
Study 26296296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain measurement
Number of subjects: 16
Study 26296296 — intervention group
Group type: COMPARATOR
Intervention: UVR exposure after IPL
Number of subjects: 16
Study 24075623 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based weight management program (2-year intervention)
Number of subjects: 1093
Study 21134472 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antidepressant medication (tricyclic, typical serotonin‐norepinephrine reuptake inhibitor, or typical selective serotonin reuptake inhibitor)
Number of subjects: 61
Study 21134472 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM applied to gray matter
Number of subjects: 61
Study 21134472 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM applied to white matter
Number of subjects: 61
Study 19244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Determine SR test
Number of subjects: 789
Study 19244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinity Biotech Capillus SR test
Number of subjects: 789
Study 19244458 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel SR tests
Number of subjects: 789
Study 19244458 — intervention group
Group type: COMPARATOR
Intervention: Parallel ELISA tests
Number of subjects: 789
Study 17968021 — intervention group
Group type: EXPERIMENTAL
Intervention: VCAP-AMP-VECP
Number of subjects: 118
Study 17968021 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 118
Study 15378145 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine administered in 2 or 3 divided doses daily (Group I)
Number of subjects: 39
Study 15378145 — intervention group
Group type: COMPARATOR
Intervention: Colchicine administered as a single daily dose (Group II)
Number of subjects: 39
Study 11469730 — intervention group
Group type: EXPERIMENTAL
Intervention: General Function Score (GFS)
Number of subjects: 297
Study 9743895 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 31710 (75 mg)
Number of subjects: 24
Study 9743895 — intervention group
Group type: COMPARATOR
Intervention: Org 31710 (10, 25, 50, or 75 mg)
Number of subjects: 24
Study 7942055 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically induced cycling with complete epidural anaesthesia
Number of subjects: 8
Study 7942055 — intervention group
Group type: COMPARATOR
Intervention: Voluntary exercise
Number of subjects: 8
Study 3169216 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (2.0 mg cumulative dose)
Number of subjects: 0
Study 3169216 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (4 mg cumulative dose)
Number of subjects: 0
Study 3169216 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 3169216 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 0
Study 30971134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture-based education (Group 2)
Number of subjects: 408
Study 30971134 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-leader education (Group 3)
Number of subjects: 408
Study 30971134 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 408
Study 28831957 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% energy, average 43 g/d)
Number of subjects: 100
Study 28831957 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstaining from walnut consumption)
Number of subjects: 100
Study 25925591 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg) intravenously prior to loading dose of ticagrelor (180 mg)
Number of subjects: 100
Study 25925591 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to loading dose of ticagrelor (180 mg)
Number of subjects: 100
Study 23108496 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 μg/kg)
Number of subjects: 56
Study 23108496 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 56
Study 22133036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) therapy
Number of subjects: 17
Study 22133036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) without corticosteroids
Number of subjects: 17
Study 22133036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) with corticosteroids
Number of subjects: 17
Study 22133036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate polyglutamate concentrations
Number of subjects: 17
Study 19637519 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Protect
Number of subjects: 36
Study 19637519 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSens
Number of subjects: 36
Study 19637519 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposen
Number of subjects: 36
Study 19637519 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study 16982274 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon points, Epiphany Primer, and Root Canal Sealant
Number of subjects: 30
Study 16982274 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha and Kerr Pulp Canal Sealer EWT
Number of subjects: 30
Study 15600229 — intervention group
Group type: EXPERIMENTAL
Intervention: Aware group (AG)
Number of subjects: 68
Study 15600229 — intervention group
Group type: COMPARATOR
Intervention: Unaware group (UG)
Number of subjects: 68
Study 11251748 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions of advance directives
Number of subjects: 686
Study 9210853 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presentation of word pairs as prime-target pairs in a lexical decision task
Number of subjects: 0
Study 9210853 — intervention group
Group type: COMPARATOR
Intervention: Neutral pairs
Number of subjects: 0
Study 8236142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarulplase 20 mg
Number of subjects: 6
Study 8236142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarulplase 40 mg
Number of subjects: 6
Study 8236142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarulplase (both doses)
Number of subjects: 6
Study 3652656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanic acid (Timentin)
Number of subjects: 224
Study 3652656 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 224
Study 31360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer technology's audio-visual facility
Number of subjects: 0
Study 31360536 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of baseline PRO responses prior to follow-up questionnaires
Number of subjects: 0
Study 31360536 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of completing a questionnaire independently of previous responses
Number of subjects: 0
Study 27843051 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone/Estradiol (DRSP/E2)
Number of subjects: 24
Study 27843051 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (T)
Number of subjects: 24
Study 27074034 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined H1R and H2R antagonist (fexofenadine and ranitidine)
Number of subjects: 49
Study 27074034 — intervention group
Group type: COMPARATOR
Intervention: Control placebo
Number of subjects: 49
Study 24933238 — intervention group
Group type: EXPERIMENTAL
Intervention: Denervation group (surgical denervation by excision of 1 cm of proximal thoracodorsal nerve)
Number of subjects: 28
Study 24933238 — intervention group
Group type: COMPARATOR
Intervention: Innervation group (thoracodorsal nerve saved intact)
Number of subjects: 28
Study 24933238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (denervated and innervated)
Number of subjects: 28
Study 22646304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirths (105 total, 65 fresh)
Number of subjects: 221
Study 22646304 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths (116 total, 87 early)
Number of subjects: 221
Study 22646304 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays in care (201 individual delays in 121/187 birth narratives)
Number of subjects: 221
Study 22646304 — intervention group
Group type: EXPERIMENTAL
Intervention: Delays in seeking care
Number of subjects: 221
Study 19783589 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate (SR)
Number of subjects: 0
Study 17583098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen tablets (standardized tablet at different doses)
Number of subjects: 0
Study 17583098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass allergen tablets
Number of subjects: 0
Study 17583098 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 15309971 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX 1200 mg orally/day for 6 months
Number of subjects: 18
Study 15309971 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months followed by PTX for another 6 months
Number of subjects: 18
Study 12645166 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-I regimen
Number of subjects: 90
Study 12645166 — intervention group
Group type: COMPARATOR
Intervention: Group-II regimen
Number of subjects: 90
Study 12645166 — intervention group
Group type: COMPARATOR
Intervention: Group-III regimen
Number of subjects: 90
Study 10734372 — intervention group
Group type: EXPERIMENTAL
Intervention: Androhep®
Number of subjects: 1431
Study 10734372 — intervention group
Group type: COMPARATOR
Intervention: X-CELL(TM)
Number of subjects: 1431
Study 7753895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee A (USA)
Number of subjects: 20
Study 7753895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee B (treated from Europe)
Number of subjects: 20